Cellectis Stock: price and insider trades · France

Headquartered in France, France, Cellectis belongs to the Healthcare & Pharma sector and traces its origins to 1999. Filings by its managers are published through AMF. Over the twelve months to 18 October 2026, 19 filings were filed, from 10 insiders.

Open-market activity splits into 4 purchases totalling €212k and 8 sales totalling €2.1M; 3 insiders sit on the buying side and 4 insiders on the selling side. The totals do not cover 1 filing with an undisclosed amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The buyers include 2 senior executives and 1 finance chief. Andre Choulika filed the largest sale, €1.3M, on 3 June 2026, which represents 0.40% of the company's market value.

For context, the typical company on the same exchange (median of 316 companies) published 6 filings over the same period, against 19 filings here. Our records for Cellectis go back to 2023, with 4 purchases and 8 sales on the open market in total.

Within a 30-day window, 1 purchase overlapped with buying by a second insider. Purchases made close together by different insiders form what is called a cluster. The last insider purchase was made public on 29 September 2026, 18 days ago. The median gap between a trade and its publication by AMF is 5 days. For comparison, MAR article 19 gives managers three business days to notify a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.

In the same sector, recent insider purchases at Cooper Companies, Inc. and Cytosorbents Corp also feature in our signals. This summary is built from AMF disclosures alone and does not predict where the share price will go.